Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers.

IF 15.1 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Annual review of medicine Pub Date : 2024-11-13 DOI:10.1146/annurev-med-050223-112834

Katarina Jankovic, Ian M Gralnek, Halim Awadie

引用次数: 0

Abstract

Acid-related disorders represent a significant global health burden. Pharmacological treatment of these conditions has at times been challenged and limited by incomplete effectiveness, antibiotic resistance, adverse medication effects and/or interactions, and disease recurrence. Since the early 1990s, the mainstay of treatment has been proton pump inhibitors (PPIs). Recently, the US Food and Drug Administration issued a clearance for vonoprazan, a potassium-competitive acid blocker (PCAB). PCABs are a new class of acid-suppressing agents that may overcome some of these challenges. The aim of this review is to evaluate and compare the emerging long-term risks of PPI and PCAB therapies.

查看原文本刊更多论文

使用质子泵抑制剂和钾竞争性酸阻滞剂的新长期风险。

与酸有关的疾病给全球健康带来沉重负担。针对这些疾病的药物治疗有时会受到疗效不全、抗生素耐药性、药物不良反应和/或相互作用以及疾病复发的挑战和限制。自 20 世纪 90 年代初以来，质子泵抑制剂（PPI）一直是治疗的主要药物。最近，美国食品和药物管理局批准了钾竞争性酸阻滞剂（PCAB）vonoprazan 的上市。PCABs 是一类新型抑酸剂，可以克服其中的一些挑战。本综述旨在评估和比较 PPI 和 PCAB 疗法新出现的长期风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annual review of medicine 医学-医学：内科

CiteScore

24.90

自引率

0.00%

发文量

期刊介绍： The Annual Review of Medicine, which has been published since 1950, focuses on important advancements in diverse areas of medicine. These include AIDS/HIV, cardiology, clinical pharmacology, dermatology, endocrinology/metabolism, gastroenterology, genetics, immunology, infectious disease, neurology, oncology/hematology, pediatrics, psychiatry, pulmonology, reproductive medicine, and surgery. The journal's current volume has transitioned from a gated access model to an open access model through the Annual Reviews' Subscribe to Open program. All articles published in the journal are now available under a CC BY license.